G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt/β-Catenin Research

Executive Summary: G007-LK is a potent, selective inhibitor of tankyrase 1 and tankyrase 2 (TNKS1/2), effectively inhibiting poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively, under in vitro conditions (Jia et al., 2017, DOI). In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter activity with an IC₅₀ of 0.05 μM (APExBIO, product page). In APC-mutant colorectal cancer models, it induces dynamic degradasome formation leading to β-catenin degradation and stabilization of AXIN1/2. G007-LK demonstrates in vivo efficacy by reducing tumor growth and protein levels of TNKS1/2 and β-catenin. The compound is primarily used for research on Wnt/β-catenin signaling and related cancer biology, particularly colorectal and hepatocellular carcinoma (Jia et al., 2017).

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases (PARPs) involved in regulating protein stability, telomere maintenance, and signal transduction. TNKS1/2 regulate the Wnt/β-catenin pathway by controlling AXIN1/2 degradation, thereby modulating β-catenin levels. Hyperactivation of tankyrases is associated with oncogenic Wnt signaling in colorectal and hepatocellular carcinoma, especially in tumors harboring APC mutations (Jia et al., 2017). Inhibiting tankyrase activity disrupts poly(ADP-ribosyl)ation, stabilizing AXIN1/2 and promoting β-catenin degradation. This mechanism is therapeutically relevant in cancers with Wnt/β-catenin pathway dysregulation. Additionally, tankyrase activity modulates the Hippo-YAP pathway by regulating angiomotin proteins (AMOTL1/2), which further impacts cancer cell proliferation (Jia et al., 2017).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a small-molecule inhibitor that selectively targets the catalytic PARP domains of TNKS1 and TNKS2. It prevents auto-poly(ADP-ribosyl)ation, leading to loss of E3 ligase recruitment and impaired ubiquitination and degradation of AXIN1/2. This results in the accumulation of AXIN1/2, assembly of degradasomes (containing phosphorylated β-catenin, β-TrCP, and ubiquitin), and subsequent β-catenin degradation. In cellular models, G007-LK suppresses Wnt signaling by reducing cytosolic and nuclear β-catenin (IC₅₀ = 0.05 μM in Wnt3a-induced HEK 293 cells; APExBIO). In vivo, it decreases tumor growth and protein levels of TNKS1/2 and β-catenin while stabilizing AXIN1/2 in xenograft mouse models. G007-LK also downregulates YAP activity by stabilizing AMOTL1/2, negative regulators of YAP, resulting in Hippo pathway modulation (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits auto-poly(ADP-ribosyl)ation of TNKS1 (IC₅₀ = 46 nM) and TNKS2 (IC₅₀ = 25 nM) in biochemical assays (APExBIO).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter (ST-Luc) with an IC₅₀ of 0.05 μM (APExBIO).
• G007-LK induces formation of AXIN-based degradasomes, leading to β-catenin degradation in APC-mutant colorectal cancer cell lines (e.g., SW480) (Jia et al., 2017).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor volume and decreases β-catenin and TNKS1/2 levels while increasing AXIN1/2 stability (Jia et al., 2017).
• G007-LK downregulates YAP protein and target gene expression, modulating the Hippo pathway in hepatocellular carcinoma cells (Jia et al., 2017).
• Tankyrase inhibitors synergize with MEK and AKT inhibitors to further suppress cancer cell proliferation (Jia et al., 2017).

For a deeper mechanistic exploration of β-catenin degradation and AXIN1/2 stabilization, see this article, which details the molecular assembly and dynamics of degradasomes. The present article extends those insights with updated in vivo and Hippo pathway data.

For an overview of nanomolar efficacy and selectivity benchmarks, this review provides foundational data. Here, we clarify translational outcomes and workflow considerations.

For advanced strategies in AXIN1/2 stabilization and Wnt pathway inhibition, this resource focuses on targeted application. The current article updates with cross-pathway (Hippo/Wnt) benchmarks.

Applications, Limits & Misconceptions

G007-LK is used for dissecting tankyrase function, Wnt/β-catenin signaling, Hippo pathway modulation, and cancer biology. Its principal applications include:

• Investigating Wnt/β-catenin pathway inhibition in APC-mutant colorectal cancer cell lines.
• Studying Hippo-YAP signaling cross-talk in hepatic and colorectal cancer models.
• Elucidating mechanisms of β-catenin degradation and AXIN1/2 stabilization.
• Evaluating tumor growth suppression in xenograft models.
• Assessing synergy with other pathway inhibitors (e.g., MEK, AKT).

Common Pitfalls or Misconceptions

• G007-LK is not suitable for direct clinical use; it is a research tool only (APExBIO).
• The compound is poorly soluble in water and ethanol; DMSO (≥26.5 mg/mL) is required for stock solutions (APExBIO).
• Long-term storage of G007-LK in solution leads to degradation; solid storage at -20°C is recommended (APExBIO).
• Effects may be context-dependent; non-canonical Wnt or Hippo pathway alterations can yield variable responses (Jia et al., 2017).
• Not all cancer types respond to tankyrase inhibition; efficacy is primarily established in APC-mutant and Wnt-activated models.

Workflow Integration & Parameters

For optimal results, G007-LK should be dissolved in DMSO at ≥26.5 mg/mL. Pre-warming at 37°C or ultrasonic bath treatment enhances solubility. Solutions should be freshly prepared; avoid long-term storage in solution. The recommended storage for the solid is -20°C. Dosing in cell lines typically ranges from 10 nM to 1 μM, with effective Wnt pathway inhibition at 50 nM in reporter assays. In vivo, dosing regimens should be based on xenograft model optimization and published benchmarks (Jia et al., 2017).

APExBIO supplies G007-LK as catalog number B5830. For detailed protocols and technical support, refer to the G007-LK tankyrase 1/2 inhibitor product page.

Conclusion & Outlook

G007-LK is a validated, selective inhibitor of tankyrase 1/2, enabling precise modulation of Wnt/β-catenin and Hippo-YAP signaling in preclinical cancer research. Its nanomolar potency, specificity, and robust activity in APC-mutant models position it as a reference tool for dissecting poly(ADP-ribosyl)ation-dependent oncogenic pathways. Future research should focus on combinatorial strategies and context-dependent effects. For reproducible, mechanistically grounded studies, G007-LK from APExBIO remains a gold standard reagent.